Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study

被引：0
|
作者：
Kensei Tobinai
Toshiki Uchida
Noriko Fukuhara
Tomoaki Nishikawa
机构：
[1] National Cancer Center Hospital,Department of Hematology
[2] Japanese Red Cross Nagoya Daini Hospital,undefined
[3] Tohoku University Hospital,undefined
[4] Janssen Pharmaceutical K.K.,undefined
来源：
International Journal of Hematology | 2019年 / 109卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：366 / 368
页数：2
相关论文
共 50 条
  • [1] Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study
    Tobinai, Kensei
    Uchida, Toshiki
    Fukuhara, Noriko
    Nishikawa, Tomoaki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (03) : 366 - 368
  • [2] Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib
    Shadman, Mazyar
    Sharman, Jeff P.
    Levy, Moshe Y.
    Misleh, Jamal
    Zafar, Syed F.
    Freeman, Benjamin B.
    Burke, John M.
    Cultrera, Jennifer L.
    Yimer, Habte A.
    Chen, Dih-Yih
    Zhang, Xiaoping
    Cohen, Aileen
    Ro, Sunhee
    Huang, Jane
    Flinn, Ian W.
    BLOOD, 2020, 136
  • [3] Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma
    Maruyama, Dai
    Nagai, Hirokazu
    Fukuhara, Noriko
    Kitano, Toshiyuki
    Ishikawa, Takayuki
    Nishikawa, Tomoaki
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2019, 59 (02) : 98 - 100
  • [4] Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies
    Munakata, Wataru
    Ando, Kiyoshi
    Yokoyama, Masahiro
    Fukuhara, Noriko
    Yamamoto, Kazuhito
    Fukuhara, Suguru
    Ohmachi, Ken
    Mishima, Yuko
    Ichikawa, Satoshi
    Ogiya, Daisuke
    Aoi, Arata
    Hatsumichi, Masahiro
    Tobinai, Kensei
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (04) : 553 - 562
  • [5] Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies
    Wataru Munakata
    Kiyoshi Ando
    Masahiro Yokoyama
    Noriko Fukuhara
    Kazuhito Yamamoto
    Suguru Fukuhara
    Ken Ohmachi
    Yuko Mishima
    Satoshi Ichikawa
    Daisuke Ogiya
    Arata Aoi
    Masahiro Hatsumichi
    Kensei Tobinai
    International Journal of Hematology, 2023, 117 : 553 - 562
  • [6] Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study
    Izutsu, Koji
    Ando, Kiyoshi
    Ennishi, Daisuke
    Shibayama, Hirohiko
    Suzumiya, Junji
    Yamamoto, Kazuhito
    Ichikawa, Satoshi
    Kato, Koji
    Kumagai, Kyoya
    Patel, Priti
    Iizumi, Sakura
    Hayashi, Nobuya
    Kawasumi, Hisashi
    Murayama, Kosho
    Nagai, Hirokazu
    CANCER SCIENCE, 2021, 112 (06) : 2405 - 2415
  • [7] Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies
    Kensei Tobinai
    Michinori Ogura
    Kenichi Ishizawa
    Tatsuya Suzuki
    Wataru Munakata
    Toshiki Uchida
    Tomohiro Aoki
    Takanobu Morishita
    Yoko Ushijima
    Satoko Takahara
    International Journal of Hematology, 2016, 103 : 86 - 94
  • [8] Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies
    Tobinai, Kensei
    Ogura, Michinori
    Ishizawa, Kenichi
    Suzuki, Tatsuya
    Munakata, Wataru
    Uchida, Toshiki
    Aoki, Tomohiro
    Morishita, Takanobu
    Ushijima, Yoko
    Takahara, Satoko
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (01) : 86 - 94
  • [9] A Phase Ib Study of Linperlisib Monotherapy in Patients with Relapsed or Refractory B-Cell Malignancies
    Liu, Wei
    Huang, Yunhong
    Yang, Haiyan
    Li, Zhiming
    Cai, Zhen
    Wang, Zhen
    Liu, Lihong
    Guo, Ye
    Liu, Ligen
    Huang, Rui
    Ye, Xu
    Qiu, Lugui
    BLOOD, 2023, 142
  • [10] A Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
    Christian, Beth
    Kuruvilla, John
    Smith, Sonali
    Porcu, Pierluigi
    Ruppert, Amy S.
    Byrd, John C.
    Grever, Michael R.
    Blum, Kristie A.
    BLOOD, 2014, 124 (21)
12345